New CEO for Anteo Technologies

Latest News

Anteo Technologies (ASX:ADO) has appointed the former of Roche Diagnostics in the UK and Ireland, Christopher Parker, as CEO following the resignation of incumbent Stefan Enderling.

Mr Enderling, who was appointed on 1 January, has decided to depart the role due to family reasons. He will remain to support the transition and formally step down on 27 April.

Mr Parker has been appointed on a short-term contract pending a search for a permanent CEO.

He has 20 years experience in both domestic and international life sciences sectors predominately through a career with Roche Diagnostics.

In his final role with the company, before retiring in the second half 2017, he was managing director for UK and Ireland. He previously held various roles in general management, marketing and business development in Canada, Asia and Australia.

According to Anteo’s Chair, Dr Jack Hamilton, “I would like to extend our appreciation to Stefan for his efforts over the past 3 months, and the time preceding his formal appointment as CEO, in assisting and guiding the company. I fully understand the family reasons behind his decision and wish him well in the future.

"The appointment of Christopher into the CEO role will ensure we maintain momentum on the Company’s battery initiative and will provide commercial strength in realising value from the Company’s life science’s portfolio.”